Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of AC2993 (exenatide) in type 2 diabetes
NCT00044668Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2002
- Primary completion
- Sep 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Aug 2002; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00044668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044668.